Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donepezil + sertraline
- Development stage
- Preclinical
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of donepezil, an acetylcholinesterase inhibitor used for Alzheimer's disease, and sertraline, a selective serotonin reuptake inhibitor (SSRI) used for depression and anxiety disorders. This combination has been studied for treating depression with cognitive impairment, showing potential benefits in improving both depression symptoms and cognitive function.
02
Targets
AcetylcholinesteraseSERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on donepezil + sertraline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donepezil + sertraline.